A Pharmacokinetic Study of Tulisokibart Administered Subcutaneously Via Autoinjector or Syringe in Healthy Adult Participants
Latest Information Update: 13 Nov 2024
Price :
$35 *
At a glance
- Drugs Tulisokibart (Primary)
- Indications Ulcerative colitis
- Focus Pharmacokinetics
- Sponsors Merck Sharp & Dohme
- 11 Nov 2024 Status changed from recruiting to active, no longer recruiting.
- 08 Oct 2024 Status changed from not yet recruiting to recruiting.
- 03 Sep 2024 New trial record